Searched for
GENERIC LEVOTHYROXINE
Alembic gets USFDA nod for generic levothyroxine sodium tabletsAlembic Pharmaceuticals has secured final approval from the US health regulator for its generic levothyroxine sodium tablets. This medicati...- Zydus Lifesciences gets USFDA nod to market generic drugThe company has received the final approval for Levothyroxine Sodium for Injection in strength of 100 mcg/vial, 200 mcg/vial, and 500 mcg/v...
- Pharma’s perennial underperformer gets a shot in the arm. Can it deliver?The stock has gained 64 per cent from March lows and 27 per cent year to date, but still 54 per cent down from its all-time high of Rs 2,12...
- Over 158 applications for generic products pending with USFDA for approval: LupinSharing information with company's shareholders, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company's US business stabilised last ...
- Add Lupin, target price Rs 890: CentrumThe brokerage expects the India business to report healthy double digit growth for the company and emerge as a key growth driver.
- Lupin posts net loss of Rs 123 crore in September quarterTotal revenue from operations stood at Rs 4,359.65 crore for the second quarter.
- Lupin launches Levothyroxine Sodium tablets in USThe tablets are indicated as replacement or supplemental therapy for hypothyroidism.
- Buy Lupin, target Rs 985: HDFC SecuritiesBuy Lupin at a price target of Rs 985.
- Buy Lupin, target Rs 1,030: HDFC SecuritiesBuy Lupin at a price target of Rs 1030.
- Lupin still on track to meet $800-million FY19 sales target: Ramesh SwaminathanThings not as bad as they were in the past and should be looking better, says Lupin CFO.
- For every rupee depreciation, we expect to add Rs 40 cr to bottom line: Ramesh Swaminathan, Lupin“Between 25% and 30% of our total exposures are hedged.”
- We expect domestic business to grow at 15%: S Ramesh, LupinI expect the price erosion to continue in America in the first two quarters at least for the current year before it stabilises around 8-10%.
- For Lupin, uncertainties of FY18 would continue in FY19: Ramesh Swaminathan“Biosimilars, complex generics and speciality would be key elements of Lupin strategy going forward”
Load More
